Treatment News : Gene Therapy Shows Promise in Controlling HIV

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » September 2013

Most Popular Links
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ


More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailprint

September 27, 2013

Gene Therapy Shows Promise in Controlling HIV

For the first time, scientists have proved that it is possible to engineer immune cells to control HIV for a sustained period of time without the need for ongoing antiretroviral (ARV) therapy. Representatives from Sangamo BioSciences presented data from the biotech company’s ongoing Phase II clinical trial of its ZFP Therapeutic, SB-728-T, at the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC).

This genetic therapy focuses on CCR5 receptors on the surface of CD4 cells. HIV latches onto these receptors in order to begin its assault. Two different genes express the CCR5 receptors, and for this therapy Sangamo researchers removed blood cells from people with HIV who were born with one non-functional version of the two genes. After knocking out the other CCR5-expressing gene, they then reinfused the genetically engineered cells into the body.

The study had a total of 11 participants. Three of them were not included in the evaluation for the ICAAC presentation because it was found they had low levels of virus that latches onto both the CCR5 and the CXCR4 receptors, and this treatment only works for virus that is “CCR5 tropic,” meaning that it only uses CCR5 receptors. One other participant is not far along enough in the study to receive an evaluation.

Three out of the remaining seven study participants achieved an undetectable viral load during an ARV treatment interruption. One maintained an undetectable level from week 11 of the treatment interruption through to week 19, when the last measurement was taken. The two other participants, however, experienced only a transient undetectable status.  

The treatment has also led to a long-term increase of CD4 cells in those treated, which was correlated to a corresponding drop in the viral reservoir, as measured by the total HIV DNA in peripheral blood mononuclear cells.

“The data…demonstrate that a single infusion of SB-728-T can lead to profound suppression of viral load in the blood and sustained functional control of the virus,” Dale Ando, MD, Sangamo’s vice president of therapeutic development and chief medical officer, said in a release. “This is the first evidence that sustained functional control of HIV in the absence of ART is possible.”

To read the Sangamo release, click here.

Search: HIV, gene therapy, CCR5, receptor, Sangamo BioSciences, ZFP Therapeutic, SB-728-T, 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy, ICAAC, CXCR4, viral reservoir, CD4, Dale Ando.


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (2 total)

 
[Go to top]


Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Poll
Are you buying holiday gifts that raise HIV/AIDS awareness?
Yes
No

Survey
Smoke Signals

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.